Value & Outcomes Spotlight is an ISPOR publication for the global HEOR community. Value & Outcomes Spotlight provides enhanced content on health policy and methodological issues and independent contributions from the field, as well as the scientific program of ISPOR Annual Meetings/Congresses/Regional Conferences, plus ISPOR news from around the world.
To receive Value & Outcomes Spotlight and other member benefits, join ISPOR.
Value & Outcomes Spotlight
March/April 2018 Vol. 4, No. 2
Medical devices is this issue’s theme, with a focus on health technology assessment (HTA) and its current struggles in the industry. Our feature article includes an interview with a current leader in the field, Eric Faulkner, vice president of Precision and Transformative Technology Solutions at Evidera, who provides insight from both the US and European perspectives. We include an additional related article on medical devices, and its relation to market access. As usual, the ISPOR Student Network gives us the vital stats in our “By the Numbers” graphics.
Also in this issue, ISPOR Chief Science Office Dick Willke gives his views on medical devices from the value assessment frameworks and real-world evidence perspectives. We also include our usual HEOR News and Research Round-Up, as well as information on future meetings, education, and other ISPOR activities.
Finally, we publish a Q&A with ISPOR 2016-2017 President Lou Garrison, who provides some insight into real-world evidence and its relation with HTA.
We hope you enjoy this issue of Value & Outcomes Spotlight! As always, we welcome your feedback and encourage you to email us at firstname.lastname@example.org
David Thompson, PhD
Value & Outcomes Spotlight Editor-in-Chief
In healthcare technology assessment (HTA) for medical devices, the problems worldwide remain in considering how a device or diagnostic has healthcare value, determining which, standards should be used in the assessment, and using those, standards to develop proper assessment tools.
Does anyone realize that the Market Access profession is actually specific to the medical industry?
An innovative methodology – idiographic clinical trials – was introduced to complement randomized controlled trials in terms of the evidence yielded, research scenarios when it can be used, suitability for applied settings, lower cost, and faster completion time.
This article raises attention to three common mistakes in stochastic modeling in health economics and outcomes research, describes the conceptual thinking behind the mistakes in an intuitive way, and provides appropriate techniques to avoid them.